Observed Signal · Sep 22, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Notable funding round in the AI for life sciences sector, highlighting growing enterprise adoption of agentic AI platforms, though not directly impacting core AdTech.
Track Dataiku Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Biolevate raised €30 million in Series A funding.
- The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures.
- Biolevate's platform can run up to 100,000 agents concurrently and has accelerated literature reviews 16-fold.
- The company is opening a US office in Boston and has doubled headcount over the past year.
- Biolevate has drafted seven patent applications, two filed in Europe.
Connected Companies & Entities
1 Entity mapped“Founded in Paris by a team of former Dataiku engineers and AI researchers....”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Health Force Raises €4.2M for Hospital AI Agents
Barcelona-based Health Force, a HealthTech startup, raised €4.2 million in Seed funding to expand its enterprise-grade AI agents for hospital operations. The round was led by LUMO Labs with participation from Step Venture, Next Tier Ventures, Target Global, and Calm/Storm. Founded in 2022 in Vienna, Health Force automates administrative tasks in hospitals, such as prior-authorisation checks, claims processing, and regulatory reporting. The company reports that its AI agents handle 75% of cases autonomously and are deployed at leading Italian hospital groups, including Humanitas and Gruppo San Donato, processing over 200,000 patient cases annually. The company plans to use the funds to expand into new workflows and European markets including Germany, France, and Spain.
sci2sci raises €1.2M for AI verification in regulated industries
Berlin-based startup sci2sci has secured €1.2 million in pre-seed funding to advance its technology for organizing and verifying data in regulated industries like biopharma and banking. The round was co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels. The company develops a neurosymbolic memory layer that transforms scattered corporate data into self-verifying knowledge. Its flagship product, Integrity Cortex, encodes information as a formal logic system where every claim must cite a literal source, and a symbolic engine verifies citations, flagging hallucinations and inconsistencies. This provides an auditable record compliant with 21 CFR Part 11. VectorCat serves as a data integration layer, connecting information across cloud and laboratory systems. Senior advisor Stephanie Bova, former Corporate VP at Novo Nordisk, has joined sci2sci. The funding will expand the engineering team, deepen customer deployments, and extend products into banking.
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.